A multicenter study evaluates the diagnostic accuracy of a novel serological marker (anti-tissue transglutaminase isoform X) for identifying celiac disease. Researchers enroll adult patients presenting with chronic diarrhea and weight loss. All patients undergo both the novel serological test and a duodenal biopsy, which serves as the gold standard for diagnosis.
The biopsy results confirm celiac disease in of the enrolled patients. Among these patients, have a positive result on the novel serological test.
Among the patients who do not have celiac disease according to the biopsy, have a negative result on the novel serological test.
Based on these study results, what is the positive likelihood ratio () of the novel serological test for diagnosing celiac disease?
Answer: 8.5